ID HEK293 CYP2C9*2-V5 AC CVCL_UG96 SY CYP2C9*2 (R144C - V5 tag) Expressing HEK293 Cell Line DR Kerafast; EWU019 DR Wikidata; Q94092983 RX PubMed=28603633; CC Characteristics: Expresses CYP2C9*2 with a C-terminal V5 tag. CC Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2623; CYP2C9 (Note=With p.Arg144Cys). CC Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo. CC Transformant: NCBI_TaxID; 28285; Adenovirus 5. CC Discontinued: Kerafast; EWU019; true. CC Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113. OX NCBI_TaxID=9606; ! Homo sapiens (Human) HI CVCL_0045 ! HEK293 SX Female AG Fetus CA Transformed cell line DT Created: 13-11-18; Last updated: 19-12-24; Version: 7 // RX PubMed=28603633; DOI=10.1002/prp2.314; PMCID=PMC5464343; RA Peterson A., Xia Z.-P., Chen G., Lazarus P.; RT "In vitro metabolism of exemestane by hepatic cytochrome P450s: impact RT of nonsynonymous polymorphisms on formation of the active metabolite RT 17beta-dihydroexemestane."; RL Pharmacol. Res. Perspect. 5:e00314.1-e00314.16(2017). //